ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 57 filers reported holding ADC THERAPEUTICS SA in Q2 2023. The put-call ratio across all filers is 37.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,896,001 | -36.2% | 916,456 | -9.3% | 0.00% | -50.0% |
| Q1 2024 | $4,536,862 | +2.3% | 1,010,437 | -62.2% | 0.00% | 0.0% |
| Q4 2023 | $4,436,865 | +86.6% | 2,672,810 | +0.9% | 0.00% | +100.0% |
| Q3 2023 | $2,377,275 | -22.4% | 2,650,251 | +86.1% | 0.00% | -50.0% |
| Q2 2023 | $3,061,920 | +87458.5% | 1,424,149 | -20.6% | 0.00% | 0.0% |
| Q1 2023 | $3,497 | -73.2% | 1,793,192 | -47.3% | 0.00% | -71.4% |
| Q4 2022 | $13,060 | -99.4% | 3,401,120 | +709.3% | 0.01% | +600.0% |
| Q3 2022 | $2,026,000 | +339.5% | 420,253 | +625.0% | 0.00% | – |
| Q2 2022 | $461,000 | -43.4% | 57,965 | +43.6% | 0.00% | – |
| Q4 2021 | $815,000 | -14.2% | 40,367 | +36.0% | 0.00% | -100.0% |
| Q4 2020 | $950,000 | -9.3% | 29,679 | -6.5% | 0.00% | 0.0% |
| Q3 2020 | $1,047,000 | +50.2% | 31,747 | +113.3% | 0.00% | 0.0% |
| Q2 2020 | $697,000 | – | 14,887 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 11,167,800 | $24,010,770 | 3.60% |
| Sio Capital Management, LLC | 4,020,705 | $8,644,516 | 2.20% |
| Redmile Group, LLC | 14,049,935 | $30,207,360 | 1.16% |
| Vantage Consulting Group Inc | 885,520 | $1,903,868 | 1.10% |
| Blue Owl Capital Holdings LP | 733,568 | $1,577,171 | 0.97% |
| AlphaCentric Advisors LLC | 778,000 | $1,672,700 | 0.93% |
| Affinity Asset Advisors, LLC | 600,000 | $1,290,000 | 0.45% |
| GCM Grosvenor Holdings, LLC | 410,888 | $883,409 | 0.38% |
| Indie Asset Partners, LLC | 93,839 | $201,754 | 0.22% |
| Frazier Life Sciences Management, L.P. | 1,647,030 | $3,541,115 | 0.21% |